Dr. Mark A. Rubin

Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer. 

Combining genetic information from a patient’s tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed.

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth.

A generous gift from Caryl and Israel Englander to Weill Cornell Medical College will expand and enhance its precision medicine program.

Prostate cancer can be driven by the same estrogen receptor responsible for the most common form of breast cancer.